Long-Term Safety of Ublituximab: Insights From the ULTIMATE Extension

This sponsored special report examines the long-term clinical profile of ublituximab in relapsing multiple sclerosis, with a focus on findings from the ULTIMATE open-label extension. Across episodes, the discussion highlights how durability of efficacy, safety over time, and clinical experience are shaping the use of anti-CD20 therapies in contemporary MS care.

Evaluating long-term safety is a critical component of understanding any chronic therapy, particularly in multiple sclerosis where patients may remain on treatment for years. In this segment, Bruce Cree, MD, PhD, clinical research director at the UCSF Multiple Sclerosis Center, reviews safety outcomes from the ULTIMATE open-label extension and how they compare with earlier trial findings.

Cree discusses rates of adverse events, infusion reactions, and infections over extended follow-up, as well as trends in immunoglobulin levels and their clinical relevance. The conversation also touches on how these findings may influence patient counseling, particularly when balancing long-term safety considerations with sustained disease control, and where continued follow-up will be essential to further define risk over time.